OBJECTIVE: To determine whether C-reactive protein (CRP) measured by a high sensitivity (hs) assay is a surrogate marker of disease activity and damage in systemic lupus erythematosus (SLE). METHODS: Five hundred eighty-eight patients with SLE participating in a multiethnic cohort (Hispanic, African American, and Caucasian) were studied. Disease activity was measured with the Systemic Lupus Activity Measure-Revised (SLAM-R) and damage with the Systemic Lupus International Collaborating Clinics (SLICC) Damage Index (SDI). hs-CRP was measured by immunometric assay. Disease activity and hs-CRP were measured at enrollment and damage accrual at last visit. The association of hs-CRP with the SLAM-R and SDI was examined by univariable (Pearson's correlation) and multivariable (linear regression) analyses. The association of hs-CRP and each individual domain of the SLAM-R and SDI was examined by Spearman's correlation. RESULTS: hs-CRP was associated with the SLAM-R in the univariable (r = 0.35, p < 0.001) and multivariable (t = 7.11, coefficient beta = 0.27, p < 0.001) analyses. It also correlated with the constitutional, eye, pulmonary, gastrointestinal, neuromotor, and laboratory domains of the SLAM-R. hs-CRP was associated with the SDI (r = 0.12, p = 0.004) in the univariable analysis but not in the multivariable analysis. When the individual domains of the SDI were analyzed, hs-CRP correlated with the renal, pulmonary, cardiovascular, musculoskeletal, and diabetes domains. CONCLUSIONS: hs-CRP was associated with disease activity but not with overall damage accrual; however, it correlated with specific domains of the damage index. hs-CRP may be useful to monitor the course of the disease and predict its intermediate outcome, but longitudinal studies with serial hs-CRP measurements are necessary to define its clinical value.
OBJECTIVE: To determine whether C-reactive protein (CRP) measured by a high sensitivity (hs) assay is a surrogate marker of disease activity and damage in systemic lupus erythematosus (SLE). METHODS: Five hundred eighty-eight patients with SLE participating in a multiethnic cohort (Hispanic, African American, and Caucasian) were studied. Disease activity was measured with the Systemic Lupus Activity Measure-Revised (SLAM-R) and damage with the Systemic Lupus International Collaborating Clinics (SLICC) Damage Index (SDI). hs-CRP was measured by immunometric assay. Disease activity and hs-CRP were measured at enrollment and damage accrual at last visit. The association of hs-CRP with the SLAM-R and SDI was examined by univariable (Pearson's correlation) and multivariable (linear regression) analyses. The association of hs-CRP and each individual domain of the SLAM-R and SDI was examined by Spearman's correlation. RESULTS: hs-CRP was associated with the SLAM-R in the univariable (r = 0.35, p < 0.001) and multivariable (t = 7.11, coefficient beta = 0.27, p < 0.001) analyses. It also correlated with the constitutional, eye, pulmonary, gastrointestinal, neuromotor, and laboratory domains of the SLAM-R. hs-CRP was associated with the SDI (r = 0.12, p = 0.004) in the univariable analysis but not in the multivariable analysis. When the individual domains of the SDI were analyzed, hs-CRP correlated with the renal, pulmonary, cardiovascular, musculoskeletal, and diabetes domains. CONCLUSIONS: hs-CRP was associated with disease activity but not with overall damage accrual; however, it correlated with specific domains of the damage index. hs-CRP may be useful to monitor the course of the disease and predict its intermediate outcome, but longitudinal studies with serial hs-CRP measurements are necessary to define its clinical value.
Authors: C H Suh; Y S Jeong; H C Park; C H Lee; J Lee; C H Song; W K Lee; Y B Park; J Song; S K Lee Journal: Clin Exp Rheumatol Date: 2001 Mar-Apr Impact factor: 4.473
Authors: E V Barnes; S Narain; A Naranjo; J Shuster; M S Segal; E S Sobel; A E Armstrong; B E Santiago; W H Reeves; H B Richards Journal: Lupus Date: 2005 Impact factor: 2.911
Authors: Luis M Vilá; Graciela S Alarcón; Gerald McGwin; Holly M Bastian; Barri J Fessler; John D Reveille Journal: J Rheumatol Date: 2005-11 Impact factor: 4.666
Authors: G S Alarcón; G McGwin; A A Bartolucci; J Roseman; J Lisse; B J Fessler; H M Bastian; A W Friedman; J D Reveille Journal: Arthritis Rheum Date: 2001-12
Authors: Ricardo Zuniga; Glen S Markowitz; Thaschawee Arkachaisri; Edward A Imperatore; Vivette D D'Agati; Jane E Salmon Journal: Arthritis Rheum Date: 2003-02
Authors: Andrew I Russell; Deborah S Cunninghame Graham; Christopher Shepherd; Cheri A Roberton; John Whittaker; John Meeks; Richard J Powell; David A Isenberg; Mark J Walport; Timothy J Vyse Journal: Hum Mol Genet Date: 2003-11-25 Impact factor: 6.150
Authors: Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz Journal: Arthritis Care Res (Hoboken) Date: 2011-04 Impact factor: 4.794
Authors: S P Ardoin; L E Schanberg; C Sandborg; E Yow; H X Barnhart; K l Mieszkalski; N T Ilowite; E von Scheven; A Eberhard; D M Levy; Y Kimura; E Silverman; S L Bowyer; L Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L K Jung; L Imundo; J B Soep; A M Reed Journal: Lupus Date: 2010-10 Impact factor: 2.911
Authors: Guillermo J Pons-Estel; Luis A González; Jie Zhang; Paula I Burgos; John D Reveille; Luis M Vilá; Graciela S Alarcón Journal: Rheumatology (Oxford) Date: 2009-05-19 Impact factor: 7.580
Authors: Chi Chiu Mok; Daniel J Birmingham; Ling Yin Ho; Lee A Hebert; Brad H Rovin Journal: Arthritis Care Res (Hoboken) Date: 2013-03 Impact factor: 4.794